Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2005-06-30
2008-12-30
Kemmerer, Elizabeth C. (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S388240, C530S399000
Reexamination Certificate
active
07470769
ABSTRACT:
The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of EGFR activity is indicated.
REFERENCES:
patent: 5102789 (1992-04-01), Siegel et al.
patent: 2005/0032162 (2005-02-01), Coco et al.
Mendelsohn et al. Oncogene. 2000; 19: 6550-65.
Mendolsohn. Endocr Rel. Cancers. 2001; 8: 3-9.
Hommel et al. Biochemistry. 1991, 30: 8891-8898.
Shiah et al. JBC. 1992; 267; 33: 24034-24040.
Feild et al. The Biochemical Journal. 1992: 283: 91-98.
Rajput et al. Cancer Res. 2007; 67: 665-673.
Wells, 1990, Biochemistry 29:8509-8517.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Bork, 2000, Genome Research 10:398-400.
Skolnick et al., 2000, Trends in Biotech. 18(1):34-39.
Doerks et al., 1998, Trends in Genetics 14:248-250.
Smith et al., 1997, Nature Biotechnology 15: 1222-1223.
Brenner, 1999, Trends in Genetics 15:132-133.
Bork et al., 1996, Trends in Genetics 12:425-427.
Defeo-Jones et al. Mol Cell Bio. 1989; 9: 4083-4086.
U.S. Appl. No. 11/172,611, filed Jun. 30, 2005, Philip T. Pienkos, et al.
Wells, James A., “Additivity of Mutational Effects in Proteins,”Biochemistry, 29(37): 8509-8517 (1990).
Bowie, James U., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science, 247: 1306-1310 (1990).
Coco, Wayne M., et al., “Growth Factor Engineering by Degenerate Homoduplex Gene Family Recombination,”Nature Biotechnology, 20: 1246-1250 (2002).
Ben-Bassat, H. and Klein, B.Y., “Inhibitors of Tyrosine Kinases in the Treatment of Psoriasis,”Current Pharmaceutical Design, 6: 933-942 (2000).
Arteaga, Carlos L., “Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?”The Oncologist, 7(Suppl. 4): 31-39 (2002).
Ogiso, Hideo, et al., “Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains,”Cell, 110: 775-787 (2002).
Engler, David A., et al., “Human Epidermal Growth Factor. Distinct Roles of Tyrosine 37 and Arginine 41 in Receptor Binding as Determined by Site-Directed Mutagenesis and Nuclear Magnetic Resonance Spectroscopy,”FEBS Letters, 271(1,2): 47-50 (1990).
Bishop Jeffrey S.
Loomis A. Katrina
Monticello Daniel J.
Pienkos Philip T.
Borgeest Christina
Elmore Carolyn S.
Elmore Patent Law Group P.C.
Kemmerer Elizabeth C.
Molecular Logix, Inc.
LandOfFree
Epidermal growth factor receptor antagonists and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Epidermal growth factor receptor antagonists and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epidermal growth factor receptor antagonists and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4047297